Iconix Pharmaceuticals Announces Chemogenomics Technology Alliance and Research Collaboration Agreement With Lilly
17 November 2005 - 2:00PM
PR Newswire (US)
MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire/ -- Iconix
Pharmaceuticals, Inc., the leader in the expanding fields of
toxico- and chemogenomics, announced today that it entered into a
research and license agreement with Eli Lilly and Company
(NYSE:LLY). Iconix will receive compensation from Lilly in exchange
for access to Iconix's DrugMatrix(R) chemogenomics system and its
Drug Signatures(R) library. DrugMatrix is a reference source of
information on the genomic effects of drug and chemical treatments.
To date, Iconix scientists have analyzed DrugMatrix to discover
over 300 Drug Signatures -- sets of genes that serve as genomic
biomarkers for the prediction of the potential toxicological,
mechanistic, and side effect properties of a pre-clinical drug
candidate. Lilly will use Iconix's chemogenomics technology in
efforts to better prioritize and select candidate drug molecules
and to improve Lilly's understanding of the safety and mechanistic
profiles of new proprietary compounds prior to and during
pre-clinical development, and also during clinical development. The
research collaboration calls for the addition of new compounds and
tissues to DrugMatrix in several key areas resulting in a database
with greater depth and breadth, and additional Drug Signatures for
these new chemistry and tissue domains. Additionally, as part of
the agreement, Lilly will integrate its in-house toxicogenomics
data with that in Iconix's DrugMatrix. "Over the past several
years, toxicogenomics has been growing in importance as a critical
tool for discovery," said Jim Neal, CEO, Iconix Pharmaceuticals.
"Lilly's commitment to Iconix and its technology is further
recognition of the value of the DrugMatrix system as a means to
screen drug candidate safety and to prioritize compounds for
development. We see this as a key step in the adoption of
chemogenomics by the wider pharmaceutical industry." This
relationship is similar in scope to the collaborations Iconix
entered into with Bristol-Myers Squibb and Abbott, both in January
2004. About Iconix: Iconix Pharmaceuticals, Inc. is pioneering the
new fields of toxico- and chemogenomics, the integration of
chemistry and genomics to profile drug candidates. Iconix's
technologies enable pharmaceutical companies to increase the odds
of advancing the right compounds to the clinic, reducing attrition
rates and the costs of drug discovery. Iconix provides reference
systems and know-how to predict toxic liabilities, side effects and
mechanisms of action for drug candidates. The company has
collaborations with Bristol Myers Squibb, Abbott Laboratories,
ICOS, Schering-Plough (NYSE:SGP), AstraZeneca, Taisho
Pharmaceutical Co., Ltd., Eisai Co., Ltd. and other leading
companies. Iconix also provides research, training and support to
the U.S. Food and Drug Administration, Center for Drug Evaluation
and Research (CDER) under an agreement to advance CDER's study of
the application of genomic technologies in the regulatory approval
process. Iconix's DrugMatrix system has been installed at the FDA
for use by CDER scientists and reviewers in a diverse range of
chemogenomics applications. The company also has strategic
partnerships with leading life sciences companies including MDS
Pharma Services (TSE:MDS)(NYSE:MDZ) and GE Healthcare.
Headquartered in Mountain View, California, Iconix was founded in
1998 and is privately held. For more information, visit
http://www.iconixpharm.com/. Company Contacts: Iconix
Pharmaceuticals Alan Engelberg 650-567-5527 For Iconix
Pharmaceuticals Jennifer Larson 415-946-1074 DATASOURCE: Iconix
Pharmaceuticals, Inc. CONTACT: Alan Engelberg of Iconix
Pharmaceuticals, +1-650-567-5527, or ; or Jennifer Larson of
Weisscomm, +1-415-946-1074, or , for Iconix Pharmaceuticals Web
site: http://www.iconixpharm.com/
Copyright
Mds (NYSE:MDZ)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Mds (NYSE:MDZ)
Historical Stock Chart
Von Okt 2023 bis Okt 2024
Echtzeit-Nachrichten über Mds (New York Börse): 0 Nachrichtenartikel
Weitere Mds News-Artikel